Expert consensus on Dual Antiplatelet Therapy (DAPT) for acute coronary syndrome in Thailand: Review article

• Main Authors: R. Kunjara-Na-Ayudhya, W. Buddhari, B. Sookananchai, S. Kuanprasert, N. Chamnarnphol, A. Sukonthasarn
• Format: Journal
• Published: 2020
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85076499856&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/68013
• Institution: Chiang Mai University

© JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND | 2019. Acute coronary syndrome (ACS) is an emergency condition that may lead to severe morbidity or mortality. One factor that may improve mortality in ACS is dual antiplatelet therapy (DAPT) with a P2Y12 receptor blocker on top of aspirin. Recently, several guidelines recommended DAPT in ACS patients. This consensus aimed to summarize how to choose the appropriate DAPT for ACS patients based on guidelines and clinical trials to ensure the best patient outcomes. The recommendations of DAPT for the eight settings of ACS, which are STEMI with primary percutaneous coronary intervention (PCI), ST elevation myocardial infarction (STEMI) with fibrinolytics, STEMI without reperfusion therapy, non-ST elevation acute coronary syndrome (NSTEACS) with PCI, medically managed NSTE-ACS, maintenance DAPT in ACS, recurrent ACS, and ACS in the elderly, are reported.